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“É exatamente disso que a vida é feita, de momentos. 
Momentos que temos que passar, sendo bons ou ruins, 
para o nosso próprio aprendizado.  Nunca esquecendo do 
mais importante: Nada nessa vida é por acaso. 
Absolutamente nada.   Por isso, temos que nos preocupar 
em fazer a nossa parte, da melhor forma possível. A vida 
nem sempre segue a nossa vontade, mas ela é perfeita 
naquilo que tem que ser.” 
                                                                 Chico Xavier 
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Abstract  
 
We evaluated anti-hyperalgesic, anxiolytic and antioxidant activity of the complex containing 
myrtenol (MYR) and β-ciclodextrin (βCD) in fibromyalgia model (FM). The MYR/βCD 
complex was prepared and structurally characterized. Male Swiss mice were pretreated with 
MYR (50 mg/kg; p.o.), MYR/βCD (50 mg/kg; p.o.), pregabalin (PGB, 30 mg/kg; i.p) or vehicle. 
1h after of treatment, the mechanical hyperalgesia, grip strength test, open field (OF), novel 
object recognition test (NOR), elevated plus-maze test (EPM) and some oxidative damage 
markers were assessed. The characterization tests indicated that MYR was incorporated into 
βCD. MYR/βCD had anti-hyperalgesic effect in all days of treatment and keep this activity 
during 6 h (p < 0.001). No difference was observed in muscle strength and OF test in MYR/βCD 
compared with negative control (p > 0.05). In OR test, the group MYR/ βCD spent more time 
in novel object to the familiar object (p < 0.05). MYR/βCD increase exploration time on open 
arm (p < 0.05) in EPM. MYR/βCD decrease malondialdehyde amount (p < 0.05), increased 
catalase activity (p < 0.05) and decreased SOD/CAT ratio when compared to control (p < 0.05).  
MYR/βCD promotes an anti-hyperalgesia effect for 6 h, revealed anxiolytic-like effect, 
inhibited cognitive and motor impairment and reduce oxidative stress. 
 
Keywords: chronic pain. fibromyalgia. anxiety. monoterpene. cyclodextrin. oxidative Stress. 
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1. Introduction 
 
Fibromyalgia (FM) is a rheumatic syndrome with a spectrum of symptoms, including 
generalized chronic pain, excessive tiredness, sleep and mood, cognitive impairment, loss of 
life quality of life [1, 2]. FM is present around 2% of the world population, especially women; 
this already means economic costs estimated at more than 12,993 million euros per year in 
Spain [3, 4]. This syndrome involves multiple symptoms and comorbidities, consequently the 
ideal treatment remains undefined, requiring both pharmacological and non-pharmacological 
approaches, based on the control of the individual symptoms, mainly pain [5]. 
 Patients with FM are exposed to oxidative stress process and despite being non-
inflammatory rheumatic syndrome there are cytokines such IL-6, IL-8 [6] and IL-10 found 
altered [7]. Free radicals generated by oxidative stress result in lipid peroxidation and 
consequently can produce tissue damage. Several clinical evidences support that oxidative 
stress can also cause peripheral and central sensitization and produce changes in the nociceptive 
sensitivity threshold, producing hyperalgesia mediated by both local and spinal oxidant 
mechanisms[8]. Furthermore, the increase in oxidative stress parameters are more strongly 
associated with severity of FM [9].  
The effectiveness of current drugs to control the FM is limited and controversial, with 
patients discontinuing use due to low clinical efficacy and severe side-effects. Thus, the 
challenge is the development of new therapeutic proposals effective for the management of FM 
and others ‘dysfunctional pain’[10, 11]. The natural products (NPs), such as terpenes and 
essential oils, has been shown to be a promising and intriguing source of potential bioactive 
molecules for novel drug models capable to block or mitigate the FM symptoms [12, 13, 14, 
15]. 
Myrtenol (MYR), an alcohol monoterpene and secondary plant metabolite of the genus 
Taxus, seems to be a promising NP for treatment of FM symptoms because previous studies 
have shown therapeutic potential, such as anxiolytic [16], gastroprotective [17], anti-
inflammatory and antinociceptive properties [18]. Moreover, MYR restored the impairment of 
endogenous antioxidant enzymes activities against myocardial ischemia-reperfusion injury 
model [19]. However, it has never been evaluated in chronic non-inflammatory muscular pain 
induced by acid saline (reported to be a FM animal model), as well as if it could ameliorate 
others symptoms common in FM patients which the current treatment is relapsing into solving 
or improving poorly. 
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Controversially, some NPs, including essential oils and terpenes, have physical 
properties that depending on the pharmaceutical formulation may become problematic in 
biological administration, mainly due the poor water solubility and fleeting bioavailability that 
produces non-durable effects [20, 21]. These physical-chemical properties may also affect the 
bioavailability and therapeutic effect of the substance [22]. Therefore, the incorporation of these 
products into macrocyclic hosts, such as cyclodextrins (CDs), have been shown to be favorable 
being exploited in products that are already available in the pharmaceutical market and in new 
drug patents [21, 23, 24].  
CDs are cyclic oligosaccharide nanoparticles which provide a host system for organic 
substances since they have an internal hydrophobic cavity available to form non-covalent 
inclusion complexes with a wide variety of organic molecules of appropriate shapes and sizes 
[25, 26, 27, 28]. This interaction that occurs with the CD molecules promotes a protection to 
the complexed substance, so preventing oxidation and protecting from changes in temperature, 
humidity and even evaporation [21, 23]. This interaction becomes a powder soluble in water 
and easy to handle, facilitating its insertion into the pharmaceutical [29, 30]. Moreover, MYR 
similar to other terpenes appears to be a guest promise to be complexed into CD [21, 31].  
Thus, we aimed to evaluate the anti-hyperalgesic, emotionality and cognitive effects 
of MYR using a chronic musculoskeletal pain model in mice (a rodent fibromyalgia-like 
model), and possible action mechanism of MYR in the oxidative stress process. 
 
 
2. Material and Methods 
 
2.1. Drugs  
-cyclodextrin (βCD, ≥ 97% purity), (-)-myrtenol (MYR, ≥ 96% purity), epinephrine 
and catalase were purchased from Sigma-Aldrich (St. Louis, MO, USA), ketamine and xylazin 
were purchased from Cristália (Itabira, SP, Brazil), 
 
4.1. Preparation of samples 
The samples were prepared by techniques of physical mixture (PM), paste 
complexation (KN) and slurry complexation (SC) as described by Andrade et al. (2017). 
 In the PM method, MYR (152.23 g/mol) and βCD (1134.98 g/mol) were mechanically 
mixed by 10 min in the molar ratio of 1:1 in ambient temperature. For to prepare the PC, the 
MYR and βCD were mixed and adding then 2.0 mL of distilled water with constant manual 
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stirring until forming a paste and removed by manual trituration. Then, the material was kept 
in a desiccator until dry. Finally, SC was carried out by the addition of water (20 mL) to a 
beaker containing MYR and βCD remained under constant magnetic stirring at 150 rpm for 36 
h (Quimis Q 261A21, Brazil). Subsequently, the material was stored in the desiccator until dry 
and removed by manual trituration [32]. 
 
4.2. Thermal analysis 
Samples were characterized by differential scanning calorimetry (DSC) and 
thermogravimetry/derivate thermogravimetry (TG/DTG) as described by Andrade et al.  [29]. 
DSC curves were obtained using a DSC50 cell (Shimadzu, Japan) using a heating rate 
of 10 °C/min from 25 to 500 °C under dynamic nitrogen atmosphere (50 mL/min) in aluminum 
capsules (Al) containing ~2 mg of samples. The DSC cell was calibrated with indium (melting 
point 156.6 °C; ∆H fus = 28.5 J.g-1) and zinc (melting point 419.6 °C).  
TG/DTG curves were obtained with TGA-60 thermobalance (Shimadzu, Japan) in the 
temperature range from 25–900 °C, under dynamic nitrogen atmosphere (50 mL/min) using 
platinum capsules containing ~2 mg of samples. The TG/DTG system was verified using 
calcium oxalate monohydrate (CaC2O4.H2O) with 99.99% purity. 
 
4.3. Scanning electron microscopy (SEM) 
 The βCD, PM, PC and SC samples were analyzed according to Quintans et al.  [33]. 
 
4.4. X-ray diffraction (XRD) 
XDR patters were obtained on Simens, model D5000, as described by Menezes et al.  
[32]. 
 
2.6. Animals  
Three-month-old male Swiss mice (40-50g) were housed with free access to food and 
water, with 6-8 animals in plastic cages (30 x 37 x 16 cm), under conditions of controlled 
temperature (22 ± 2 ºC) on 12 h light/12 h dark cycle (lights on 06:00h a.m.). All experiments 
were carried out from 08:00 h a.m. to 05:00 h p.m. Experimental protocols and all procedures 
were approved by the local ethics committee of the Federal University of Sergipe (protocol 
CEPA/UFS nr.16/2017) and lo committee on the use of animals of the Federal University of 
São Paulo (protocol CEUA nr. 2888011216). All efforts were made to minimize animal pain, 
suffering or discomfort.  
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2.7. Acid saline-induced chronic muscle pain 
Prior to induction of pain, mice were anesthetized with intraperitoneal (i.p.) ketamine 
(100 mg/kg) plus xylazine (10 mg/kg). Afterwards, 20µL of acid saline (pH = 4) was injected 
into the left gastrocnemius muscle to induce chronic widespread non-inflammatory muscle 
pain. After five days, animals again animals were injected with acid saline. In this model for 
FM, bilateral mechanical hyperalgesia lasting was induced for 4 weeks after the second 
injection [34]. 
 
2.8. Pharmacological treatments 
After confirming mechanical hyperalgesia, mice were treated with MYR (50 mg/kg; 
p.o.), MYR/βCD (50 mg/kg; p.o.) or vehicle (saline 0.9%; p.o.) daily for 10 days; or pregabalin 
(PGB, 30 mg/kg, i.p.). After 1 h, animals were evaluated to behavioral tests. 
 
2.9. Mechanical hyperalgesia measurement 
Mechanical hyperalgesia was evaluated in mice as reported by Nascimento et al.  [12]. 
In a quiet room, the animals were placed in acrylic cubicles (12×10×17 cm) with wire grid 
floors and acclimatized for 30 min. This method consisted of evoking a hind paw flexion reflex 
with a hand-held force transducer (electronic analgesimeter; model EFF 301, Insight®, 
Ribeirão Preto, SP, Brazil) adapted with a polypropylene tip. Stimulus intensity was obtained 
by averaging three measurements taken with minimal intervals of 180s. The mechanical 
threshold measurements were performed three times for each animal and results were analyzed 
considering the mean value, at the following phases: before the first injection of acid saline; 24 
h after the second injection of acid saline; and 1h after treatments application of each therapeutic 
resource on consecutive days of treatment. 
 
2.10. Grip strength test 
The hindpaw and forepaw grip force was tested as previously described Quintans-
Júnior et al. [13]. The mice were allowed acclimate in apparatus twice by day for 2 days by 
performing the grip meter strength (Insight®, Ribeirão Preto-SP, Brazil). The evaluation 
consisted in holding the mice on a metal grid, so that it tended to move to the opposite side, and 
to observe the force exerted, in grams (g), by the animal's paws in the attempt to escape. The 
measurements were performed to obtain the arithmetic mean of three values on consecutive 
days of treatment. 
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2.11. Open field (OF) 
The apparatus was a circular arena with base made of wood (diameter = 84cm, height 
= 35cm) without the ceiling. The animals were placed in the center of the apparatus for free 
exploration during 5 min. The session was recorded by a camera placed above the OF at height 
of 230 cm and the behavioral parameters were registered by an animal tracking software (Any-
maze, Stoelting, USA). The behavioral evaluation included distance total traveled (in meters) 
and the average speed (in meters/second). This evaluation occurred on day 6 of the experiment. 
 
2.12. Novel Object Recognition Test (NOR) 
The task was carried out in the same arena used in the OF test.  Throughout the 
repetitions of the sessions, different objects were used, each with two copies, being of the same 
material differing in color, size and shape. The objects were weighed enough not to be moved 
by animals. After each series the objects used as well as the open field were cleaned with 5% 
alcohol to avoid the presence of olfactory tips. In training session, animals were exposed to two 
identical objects for 5 min. The same procedure was carried 1 h later (test session, duration 5 
min), except that one of the objects was replaced for a new one.  The sessions were registered 
by Any-maze. The time spent exploration each object was measured in the sessions and 
included touching with forepaws or nose, sniffing and biting the objects. The percent time 
exploring each object (time exploring old or new object/time exploring both object) was 
calculated. This evaluation occurred on day 7 of the experiment. 
 
2.13. Elevated plus-maze test (EPM) 
The test was carried out in an apparatus made of wood containing to two open arms 
(27.5 x 6.5 cm) and two enclosed (27.5 x 6.5 x 18 cm). After 60 min of the treatments animals 
were placed individually in the center of the apparatus for free exploration during 5 min. The 
session was registered by Any-maze. The behavioral evaluation included the time spent 
exploration of the open and enclosed arms. Moreover, distance total traveled (in meters) and 
the average speed (in meters/second) was calculated for each animal, registering the number of 
entries in the open/ enclosed arms and the respective residence time. The evaluation occurred 
on days 8 and 9 of the experiment. 
 
2.10. Oxidative damage markers 
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Proteins oxidative damage and effects on lipids in mice were analyzed in tissue 
samples of brain. The oxidative status of the thiol groups was assessed by quantification of the 
total reduced sulfhydryl (SH) groups. Samples were reacted with 5,50-dithionitrobis 2-
nitrobenzoic acid (10 mM) during a 60min incubation at room temperature, and the absorbance 
of the solution was read using a spectrophotometer at 412 nm [35]. 
 Lipoperoxidation was determined by the quantification of TBARS generated from the 
reaction of the thiobarbituric acid (TBA) with lipoperoxides in an acid-heating medium. After 
precipitation with 15% trichloroacetic acid, the supernatant was mixed with 0.67% TBA and 
heated in a boiling water bath for 20 min. TBARS was determined by measuring the absorbance 
at 532 nm [36]. 
Superoxide dismutase assay (SOD)  was determined from the inhibition of superoxide 
anion-dependent epinephrine autoxidation [37].  Different concentrations of protein were 
incubated at 32˚C with adrenaline and glycine buffer (pH 10.2) for 30 min and the absorbance 
at 480 nm was determined from zero to 30 min, in intervals of 30 s. And the results were 
expressed as units of SOD/mg protein [38]. 
Catalase assay (CAT) was assayed by measuring the ratio of decrease in hydrogen 
peroxide (H2O2) [39]. Thus, 50µg of protein was incubated at 32˚C with H2O2 for 10 min and 
the absorbance at 240 nm was determinate at intervals of 15 s for 5 min.  
 
2.11. Statistical analysis 
Statistical differences between the treated and control groups were evaluated by One 
way-ANOVA or two way-ANOVA followed by Bonferroni’s post hoc test, Tukey’s post hoc 
test or t-Student-Newman-Keuls test. Differences were considered statistically significant when 
p < 0.05. And all statistical analyses were performed using Graph Pad Prism (version 5.0) 
(Graph Pad Prism Software Inc., San Diego, CA, USA). Results were expressed as mean and 
standard error of the mean (mean ± SEM). 
 
3. Results 
Figure 1 (A) represents the DSC curves of MYR, βCD, PM, KN and SC.  MYR 
presented two events in the temperature range of 30-280 °C, corresponding to volatilization, 
followed by the decomposition. The curve of βCD showed a broad thermal event between 30 
and 113 °C corresponding to water release, a second endothermic event in the range of 209-234 
°C, characteristic of the crystalline phase transition and at 282-327 °C a thermal event attributed 
to the melting peak, followed by degradation of the βCD. The DSC curves of PM presented 
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four events like βCD, the KN and SC were observed disappearance of an endothermic peak 
between 209-234 °C suggesting interaction between MYR and βCD.   
 
<INSERT FIGURE 1> 
 
The TG/DTG analysis curves illustrated (Figure 1 B) the mass loss percentages, 
calculated from specific temperature ranges, for the MYR and the respective inclusion 
complexes, were shown in Table 1. On the curves TG/DTG, observed that the MYR lost 
88.23% (30-170 ° C) and the βCD had a loss of 13.68% of its total mass. The PM, KN and SC 
lost 22.93%, 11.98% and 14.25%, respectively. In the second stage (170-280 °C), we observed 
that PM, KN and SC presented a mass loss of 1.28%, 4.55% and 3.88%, respectively. In the 
third phase, KN and SC showed a greater loss of mass, possibly due to the release of MYR 
present in the internal cavity of βCD. There results suggested possible inclusion complexes 
formation by KN and SC methods. 
 
<INSERT TABLE 1> 
 
Figure 2 displays the photomicrographs obtained with Scanning Electron Microscopy 
(SEM) and represents the morphological alterations linked to the host-guest interactions. The 
results show that βCD, PM and KN present square and rectangular crystals of different sizes.  
SEM of SC exhibited loss of rectangular-shaped crystals and smaller particles, suggesting 
interaction between MYR and CD by this method. 
 
<INSERT FIGURE 2> 
 
The diffractograms of βCD, MF, KN and SC were shown in Figure 3. It was possible 
to observe that the βCD peaks presented characteristic pattern of a crystalline compound, as 
well as in KN and SC. However, in the diffractograms of KN and SC the disappearance and the 
appearance of new peaks were also observed, suggesting the formation of a new crystalline 
phase due to the interaction MYR/CD. 
 
<INSERT FIGURE 3> 
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The results of the hyperalgesia evaluation showed that 24 h after the second injection 
of acid saline in the gastrocnemius muscle there was a decrease in paw withdrawal threshold 
and this effect persisted throughout all the evaluation days. MYR/βCD group showed an 
increase of the paw withdrawal threshold for a period about 6 h when compared to control (p < 
0.001). However, no effects were observed in the MYR group (p > 0.05, Figure 4A). 
In the daily assessment, MYR/βCD group demonstrated a significant reduction of 
hyperalgesic behavior when compared to control group (p < 0.001). MYR alone exhibit 
significant changes in painful behavior only on the days 9 and 14. In addition, no tolerance 
effects were observed in the MYR and MRY/ βCD groups (Figure 4B), as well as muscle 
strength (Figure 4C). 
 
<INSERT FIGURE 4> 
 
No differences were observed distance traveled and speed mean in the treated-groups 
(Figure 5A and 5B).  
 
<INSERT FIGURE 5> 
 
In NOR test no differences was observed among groups in the training session (Figure 
6A). In the test session differences were found for the saline acid animals, suggesting deficit in 
short-term memory. On the other hand, PGB and MYR/βCD groups spent more time exploring 
the new object in comparison to the familiar object (Figure 6B). 
 
<INSERT FIGURE 6> 
 
In relation to EPM test, PGB and MYR/ MYR/βCD groups showed an increase in the 
percentage of time spent in the open arms when compared to control exploration time (p < 0.05, 
Figure 7C), suggesting decrease in anxiety-like behavior. No differences were found in  mean 
speed and distance traveled (Figure 7 A and B). 
 
<INSERT FIGURE 7> 
 
As showed in Figure 8, some oxidative parameters were assessed. Results 
demonstrated that MYR/βCD significantly decreased (p<0.05) MDA formation, consistent with 
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lipid peroxidation, in brain of FM mice (Figure 8A). Moreover, Figure 8D and E demonstrated 
a significant upregulated catalase activity (p<0.05) and a significant (p<0.05) decreased 
SOD/CAT ratio to MYR/βCD group when compared with controls. No alterations were found 
in SH and SOD (Figure 8B and 8C). 
 
<INSERT FIGURE 8> 
 
4. Discussion 
FM is considered one of the most important non-inflammatory rheumatic diseases due 
to the related comorbidities and the difficulty of treatment, as it is a type of ‘dysfunctional pain’ 
has been considered as a ‘neglected pain’ due poor therapeutic options today  [11, 15, 40]. Thus, 
the search for new therapeutic options is a great challenge for modern medicine and PNs have 
been shaping an inexhaustible source of new chemical entities. 
Herewith we investigated the pharmacological effects of the inclusion complex 
containing MYR and βCD in mice submitted to a chronic widespread non-inflammatory muscle 
pain model (an animal model for FM). Our main results showed anti-hyperalgesic, anxiolytic 
like behavior and antioxidant profile.  
Different analytical techniques, such as DSC, TG/DTG, SEM and XRD, were used to 
characterize and compare the physicochemical properties of MYR and βCD prepared solids, 
investigating and comparing the potential and efficacy of different preparation methods. The 
DSC curves of PM presented four events like βCD, the KN and SC were observed 
disappearance of an endothermic peak between 209-234 °C suggesting interaction between 
MYR and βCD. Previous studies reported similar results to others NPs such as were observed 
in the carvacrol/CD [40] and limonene/CD complexes [28]. 
In TG analysis, the PM, KN and SC lost in different stages also were observed in other 
studies with inclusion complex carvacrol/-CD [32]. According to Hadaruga et al. [41] the first 
weight loss corresponding to water release, takes place in the complexation process because 
some water molecules are replaced by hydrophobic molecules. The paste and slurry complexes, 
weight loss continued after 250ºC, indicating that the inclusion complex increases the stability 
of monoterpenes [42]. 
By data analysis obtained by SEM is possible to investigate of the morphological 
aspects of the solid surface, helping to evidence morphological alterations that may be related 
to host-host interactions, besides providing information about possible new solid phases [43]. 
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In one of the studies carried by our group, Quintans et al.  [33] reported similar results in the 
hecogenin acetate/CD complexes according that the new solid phase formation was 
characteristic of inclusion complexes between curcumin and CD [44]. The complexation 
between MYR and βCD by the KN and SC methods were represented as agglomerates. In 
contrast, the particle morphology corresponding to MF was like the β-CD. These differences 
are due to the stacking interactions that occur with the CDs compared to the complexes formed 
but the morphology of the complex is not the only indicator of complex formation [45]. 
Considering the data obtained of the characterization, we demonstrated the formation 
of the complex containing MYR and βCD by the KN and SC methods. These results suggest 
that is feasible to study the pharmacological action of MYR/βCD obtained by SC method.  
Afterward we confirmed the formation of the inclusion complex containing 
MYR/βCD and starting from the background of the analgesic profile already described for this 
terpene, we assessed it in a mice fibromyalgia-like model. We chose the model described by  
Sluka et al.  [34] due the consistent hyperalgesia provoked by saline acid injection administered 
within gastrocnemius muscle, producing a chronic widespread non-inflammatory muscle pain 
and due other behavioral changes that are also related to the symptoms presented by 
fibromyalgic patients [34, 46]. Therefore, MYR/βCD had significant anti-hyperalgesic profile 
while the MYR alone exhibit significant changes in painful behavior in this animal model only 
on the days 9 and 14 maybe by pharmacokinetic parameters. Thus, the complexation with βCD 
was essential to provide an improvement of pharmacological effect of MYR when administered 
by oral route.  
These noncovalent complexes offer a variety of physicochemical advantages drugs 
including the possibility for increased water solubility and solution stability [47]. Recent studies 
have reported that βCD can improve the anti-hyperalgesic effects of terpenes, mainly 
monoterpene, which appears to be related to the improvement of bioavailability and physico-
chemical properties [14, 25, 28,  33]. Recent systematic review corroborates with our hypothesis 
which associates the use of CDs to improve the efficacy and bioavailability of analgesic and 
anti-inflammatory compounds already available from the pharmaceutical market, especially 
when the active principle is an apolar compound [21, 24, 48, 49]. Interestingly, this approach 
has suggested that it can be a way to reduce the therapeutic doses improving pharmacological 
efficacy and  the possibility of adverse events related to the use of drugs as well as their potential 
toxicity [48, 49]. To the best of our knowledge, this is the first scientific report showing a 
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possible applicability of MYR under chronic conditions, such as FM to reduce hyperalgesia and 
anxiety. 
MYR/βCD was also able to increase mechanical hyperalgesia withdrawal thresholds in 
chronic assay with no muscle relaxation. Although the antinociceptive and anti-inflammatory 
properties of MYR has already been described for other experimental models (acute models) 
little is known about its CNS effects or myorelaxant [16, 18]. MYR  can act in the glutamatergic 
system [18] and high concentrations of glutamate and receptor NMDA in posterior insula have 
play important role in the FM pathophysiology  [49, 50]. Moreover, glutamate and its receptors 
are important targets for anti-hiperalgesyc drugs because the activation of glutamatergic system 
is associated to the development and maintenance of hyperalgesia [51, 52].   
Furthermore, MYR can acts as positive allosteric modulator of synaptic and 
extrasynaptic GABAA receptors, thereby it may augmenting phasic and tonic GABAergic 
inhibition  [17, 51]. This modulation contributes to depressant effect of CNS but not affect 
muscle capacity, a side-effect common in the drugs used in FM treatment management [51]. 
The CNS depression and muscle relaxation effect can reduce the response of motor 
coordination and might upset the painful behavior test results found in FM animal model  [13, 
52]. So, we analyzed the muscle relaxation of MYR/βCD on the grip-strength meter, so unchanged 
force was observed in treated animals. The results reinforce the hypothesis that MYR produces anti-
hyperalgesic profile, but it was not due to a feasible muscle relaxation or inhibitory effect on the 
CNS, at least in tested doses. It was corroborated by Silva et al.  [18] that equally reported that the 
antinociceptive effect exerted by MYR is not related to changes in the motor coordination of 
animals. 
The possible effect on the emotionality in any experimental FM animal models is rare 
in the literature, which is very strange and unaccountable because FM comorbidities are an 
abyss to overcome in the clinic approaches [52]. Herein we also assessed how the treatment 
with MYR or MYR/βCD may influence in the behavior of animals. 
The Open-field test (OF) are usually explained in terms of emotionality, stress-
susceptibility, exploration or coping style [53]. We performed the OF to evaluate locomotor 
and exploratory activities (considered also an important aspect in the emotionality), so our 
results demonstrated that pretreatment with MYR or MYR/βCD do not alter the locomotor 
activity of the animals. Moreira et al. [16]  reported that MYR-treated (25, 50 and 75 mg/kg i.p) 
mice did not alterations on the number of crossing, grooming or rearing when compared with a 
negative control in OF. The unchanged motor coordination tests can be important because other 
animal models which evaluate cognitive or potential anxiolytic-like behavior, such as elevated 
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plus-maze test (EPM) and new object recognition task (NOR), can present false positive results 
if the motor function have altered [16]. 
NOR was used to investigate associative memory, since this task quantify exploration 
of objects, and delimiting memory settings [54]. Our results indicated short-term memory 
deficit in FM animals, but not in the MYR/βCD and PGB-treated mice, so showing a promising 
profile. Pain and depressive symptoms in FM patients are related, at least in part, to significant 
deficits in emotionally charged cognitive tasks and mainly affective processes involved in 
learning, memory, attention, and decision-making [55]. Thus, our result can contribute to study 
of reduction this comorbidity for FM patients.  
Furthermore, MYR/βCD and pregabalin (PGB), one of the three most important drugs 
used in the FM symptoms management, increased exploration time on open arm, so suggesting 
a possible upgrade emotionality of mice reducing an anxiety-like behavior. This result is 
newsworthy because the behaviors as pain catastrophizing, fear of pain, and pain severity are 
associated with anxiety in patients with FM [56]. The anxiolytic-like effect of this monoterpene 
can be mediated by GABAergic transmission because MYR appears to improve GABA 
neurotransmission via GABAA activation [16]. It was also demonstrated that other terpenes 
such as carvacrol [57], linalool [58], 1,4-cineole [59] and phytol [60] presented a similar effects 
of the MYR that seem to be driven by the ease of crossing the blood-cerebrospinal barrier [61]. 
In fact, the monoterpenes are molecules formed by two isoprene subunits that when showed 
any CNS depressor profile, it seems to be associated with modulation of GABAergic system  
[62, 63]. In this context, MYR showed a similar profile to PGB which has been used to 
generalized anxiety disorder, social anxiety disorder and bipolar disorder [64], because inhibit 
calcium influx and subsequent release of excitatory neurotransmitters [65]. 
FM provokes a disrupt in redox homeostasis, causing an oxidative damage and 
decreasing antioxidant defenses [9]. Moreover, several studies have shown mitochondrial 
dysfunction and high levels of oxidative stress markers in FM patients [66, 67]. The inseparable 
relationship between the increase of ROS and the reduction of endogenous antioxidant defenses, 
including superoxide dismutase (SOD), catalase (CAT) and glutathione, seems to be already 
documented with the symptoms of FM [68]. 
However, little is known about oxidative stress in FM-positive animals. The oxidative 
state of the cerebrospinal fluid (CSF) in a mice FM-like model was recently evaluated by Klein 
et al. [69].  Although the authors used an different FM animal model which experimental 
syndrome was induced by reserpine, the pretreatment with PGB, resveratrol and Rice Oil 
reduced reactive oxygen species (ROS) in CSF and suppressed behaviors related to FM 
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symptoms [69]. Brain oxidative stress has been implicated in the response to stress and in the 
pathogenesis of neurologic and psychiatric diseases, as well as to FM syndrome [70].  
To better understand if the balance of oxidative stress may be related to the 
pharmacological effect produced by MYR in mice FM-like model, we assessed the redox 
equilibrium in brain from mice of control and MYR/βCD groups. So, we demonstrated that 
MYR/βCD can prevent oxidative imbalance by decrease oxidative damage in lipids and by 
upregulate catalase activity which produces a protective profile of oxidative stress in the CNS. 
The increased lipid peroxidation can disrupt the function of biological membranes [71, 72] and 
is often associated with cognitive deficit [73]. Further, the catalase is an enzyme that 
metabolizes H2O2, releasing water and oxygen, ergo H2O2 is one of the main indicator of brain 
homeostasis and disturbance in H2O2 contend in cerebral structures was related to brain diseases 
[74]. Thus, the maintenance of oxidative homeostasis induces by MYR/βCD could be 
potentially underlying in the improvement of behavioral impairment observed in treated 
animals.  
Moreover, our result is corroborated, at least in part, by the fact that the MYR can 
restore the impairment of endogenous antioxidant enzymes activities [19]. Oral doses of 25, 50 
and 100 mg/kg  was able to significantly decrease  the activity of myeloperoxidase and 
malondialdehyde, as also can increase in glutathione peroxidase, SOD, and catalase activity in 
gastric tissues [17]. 
 The protective role of alcoholic terpenes, as MYR, in neuroprotection in animal 
models that induce strong oxidative stress seems to be easily explained by the presence of its 
hydroxyl group [75]. Thus, MYR is a probably donates hydrogen atoms with an unpaired 
electron (H•), producing another radical that is stabilized by electron scattering generated at a 
molecule resonance structure, similarly to what occurs with terpenes such as carvacrol [75] and 
linalool [76]. This protective effect of redox balance in rodents in this specific mice FM-like 
model produced by MYR is new and needs to be better explored in future work. 
 
5. Conclusion 
Together, the present study suggests that MYR can be complexed in βCD which is 
able to produce a very significant reduction of mechanical hyperalgesia, to produces an 
anxiolytic-like profile, preventing cognitive alterations caused by an animal model for FM. 
These findings seem to be related to maintenance of redox homeostasis induced by MYR/βCD. 
The complexation with βCD could enhances the pharmacological profile of this terpene maybe 
by the increase of bioavailability or by a greater water solubility of the active compound that 
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favors its biological effect. However, more studies are required for elucidate the MYR central 
action mechanisms. Thus, the results found here are stimulants for the continuation of studies 
with MYR or MYR/βCD in this painful syndrome seeking new therapeutic proposals for FM 
patients which can supply the pain and ameliorate other comorbidities equally deleterious for 
them. 
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ANEXOS 
 
FIGURES CAPTIONS 
 
Figure 1. DSC (A) and TG/DTG curves (B) of  MYR, βCD, PM, KN and SC in the molar ratios 
of 1:1 in dynamic nitrogen atmosphere (100 ml.min-1) and heat (10 °C.min-1). 
Figure 2. Scanning Electron Microscopy (SEM) images of βCD, MF, KN and SC in an increase 
of 300 and 700x. 
Figure 3. X-ray diffractogram of βCD, MF, KN and SC. 
Figure 4. Effect of acute (A) and chronic (B) administration  and assessment of muscle strength 
(C) of MYR/βCD (50 mg/kg; p.o.), MYR (50 mg/kg; p.o.) or vehicle (saline 0,9%) on 
mechanical hyperalgesia induced by acidic saline in mice. Each point represents the mean ± 
S.E.M (n = 8, per group). ***p < 0.001 vs. control group (Two-way ANOVA followed by 
Bonferroni post hoc). 
Figure 5. Effect of MYR/βCD (50 mg/kg; p.o.), MYR (50 mg/kg; p.o.), positive control (PGB 
30mg/kg ip.) or vehicle (saline 0,9%) in the open field test in fibromialgic positive mice. Each 
point represents the mean ± S.E.M (n = 8, per group). * p <0.05 negative control for all other 
groups; #p <0.05 positive control for SHAM, MYR and MYR/βCD groups; ° p <0.05 positive 
control in relation to the SHAM group; ~ p <0.05 treatment effect (ANOVA followed by 
Tukey's post hoc). 
Figure 6. Effect of MYR/βCD (50 mg/kg; p.o.), MYR (50 mg/kg; p.o.), positive control (PGB 
30mg/kg ip.) or vehicle (saline 0,9%) in training session (A) and test session (B) in novel object 
recognition task in fibromialgic positive mice.   *p <0.05 treatment effect (ANOVA followed 
by Tukey's post hoc). 
Figure 7. Effect of MYR/βCD (50 mg/kg; p.o.), MYR (50/ mg/kg; p.o.), positive control (PGB 
30mg/kg ip.) or vehicle (saline) in exploration time on open arm in EMP test in fibromialgic 
positive mice. *p <0.05 treatment effect when compared with negative control  (ANOVA 
followed by Tukey's post hoc). 
Figure 8. Effect of MYR/βCD (50 mg/kg; p.o.) or vehicle (saline) on parameters of oxidative 
imbalance in the brain of mice. A) reactive species of thiobarbituric acid (TBARS) expressed 
in % of control; B) total reduced thiol content (SH) expressed in µmol SH/ mg protein; C) Total 
SOD activity expressed in U SOD/mg protein. D) catalase activity expressed in U CAT/mg 
protein; E) ratio of SOD/CAT activities expressed in U SOD/U CAT. Data are reported as 
means ± SEM of 7 fibromialgic positive mice. Statistically significant differences from control 
group, as determined by T- test: *P < 0.05. 
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Table 1. Mass loss of MYR, βCD, PM, KN and SC in molar ratio 1:1  
 
Mass loss (%) 
SAMPLES m
1
 
30-170 °C 
m
2
  
170-280 °C 
m
3
  
280-365 °C 
m
4
  
365-900 °C 
MYR 88.23# 2.29 3.77 - 
CD 13.68* 0.48 62.45 23.41*** 
PM 22.93+ 1.28+ 66.84+ 15.78*** 
KN 11.68+ 4.55++ 74.18+++ 13.11*** 
SC 14.25+ 3.88++ 71.81+++ 12.76*** 
# Percentage of MYR 50 mg/kg; p.o.latilized up to 170 ° C; * Percentage of H2O release up to 170 ° C; + Mass 
loss related to the substitution of water molecules of β-CD by the MYR up to 170ºC; +++ loss of mass probably 
attributed to release of MYR in the range of 260 to 370 ° C; *** formation of elemental carbon due to carbonization 
of the sample in the range of 370 to 900 ° C. 
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